Current novel therapeutics for the prevention and treatment of bone loss in patients with inflammatory joint disease target cytokines and other inflammatory mediators. Mesenchymal stem cell therapy is a compelling new treatment currently being studied in clinical trials.
Current novel therapeutics for the prevention and treatment of bone loss in patients with inflammatory joint disease target cytokines and other inflammatory mediators. Mesenchymal stem cell therapy is a compelling new treatment currently being studied in clinical trials.
Nancy Lane, MD, professor of internal medicine and rheumatology from the University of California, Davis Medical Center, discussed new approaches to prevent and treat inflammatory bone loss at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
Bone loss in rheumatoid arthritis (RA) is a multi-factorial, clinically significant problem, particularly in women with concomitant osteoporosis. These patients present with both focal erosions and systemic bone loss. One key factor in systemic bone loss is systemic inflammation and damage caused by circulating cytokines.
In her talk, Dr Lane described how current novel therapeutics for systemic bone loss target inflammatory cytokines. These drugs include denosumab (a fully human IgG monoclonal antibody), anti-cytokine therapies (especially TNF blocking agents), and sclerostin inhibitors.
In one study of the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), the use of bisphosphonates improved bone loss, however the monoclonal antibody denosumab improved joint erosions, lumbar spine and total hip bone mass and also decreased bone loss.
Next, Dr Lane reviewed in vivo and in vitro studies that used mesenchymal stem cells to treat systemic bone loss. LLP2A-Alendronate, a bisphosphonate attached to a ligand that directs the mesenchymal cells to the bone surface is currently being studied with promising results. In a mouse model, this novel drug prevents age-related trabecular bone loss. In estrogen-deficient mice, it has been shown to prevent bone loss and improve cortical bone strength. Lastly, in mouse models mimicking inflammatory joint disease, LLP2A-Alendronate decreased bone erosions and improved bone growth.
At this time, a number of Phase 2 clinical trials are investigating the use of mesenchymal stem cells to treat inflammatory joint disease. Most focus on treating patients who are refractory to TNF-blockers, and they vary in the source of mesenchymal stem cells. However, they may be promising novel therapeutic options for patients in the not-too-distant future.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More